Drug Facts
Composition & Profile
Identifiers & Packaging
16 HOW SUPPLIED/STORAGE AND HANDLING ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution is a clear, pale-yellow to yellow viscous liquid available in 4 presentations. Each single-dose glass vial is filled with a solution of 29.25 mg/mL bupivacaine and 0.88 mg/mL meloxicam. Each presentation described below is supplied in the ZYNRELEF kit containing a vial (packaged in an individual carton) along with sterile, individually packaged components for administration. Product Presentation (Kit Supplied with Vial Access Needle) Vial Access Needle Provided Luer Lock Syringe(s) Provided Luer Lock Applicator(s) Provided Syringe Tip Cap(s) Provided NDC Bupivacaine/Meloxicam Net Quantity Volume Each ZYNRELEF vial contains overfill to compensate for residual amounts that remain in the vial, vial access needle, Luer lock applicator, and syringe(s) during drug withdrawal and administration 47426-501-02 400 mg/12 mg 14 mL 1 × 20 mL 2 × 12 mL 2 2 47426-502-02 300 mg/9 mg 10.5 mL 1 × 20 mL 1 × 12 mL 1 1 47426-503-01 200 mg/6 mg 7 mL 1 × 10 mL 1 × 12 mL 1 1 47426-504-01 60 mg/1.8 mg 2.3 mL 1 × 10 mL 1 × 3 mL 1 1 Product Presentation (Kit Supplied with Vented Vial Spike) Vented Vial Spike Provided Luer Lock Syringe(s) Provided Luer Lock Applicator(s) Provided Syringe Tip Cap(s) Provided NDC Bupivacaine/Meloxicam Net Quantity Volume Each ZYNRELEF vial contains overfill to compensate for residual amounts that remain in the vial, vented vial spike, Luer lock applicator, and syringe(s) during drug withdrawal and administration 47426-301-02 400 mg/12 mg 14 mL 1 2 × 12 mL 2 2 47426-302-02 300 mg/9 mg 10.5 mL 1 1 × 12 mL 1 1 47426-303-01 200 mg/6 mg 7 mL 1 1 × 12 mL 1 1 47426-304-01 60 mg/1.8 mg 2.3 mL 1 1 × 3 mL 1 1 The following replacement components are individually supplied separate from the kit: Carton containing 5 vented vial spikes Carton containing 10 Luer lock applicators Carton containing 10 sterile 3 mL Luer lock syringes Carton containing 8 sterile 12 mL Luer lock syringes Carton containing 8 sterile 10 mL vial access needles Carton containing 6 sterile 20 mL vial access needles Storage Store ZYNRELEF kits at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. If ZYNRELEF vials are removed from the kit, store them at controlled room temperature. Protect from light during storage.; PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 400 mg bupivacaine and 12 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-301-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 400 mg bupivacaine and 12 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike Two sterile 12 mL Luer Lock syringes Two sterile Luer lock applicators Two sterile syringe tip caps Instructions for Use and Prescribing Information Vial Contents: 14 mL* Withdraw 14 mL to deliver 13.5 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL; PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 300 mg bupivacaine and 9 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-302-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 300 mg bupivacaine and 9 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 10.5 mL* Withdraw 10.5 mL to deliver 10.2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL; PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 200 mg bupivacaine and 6 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-303-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 200 mg bupivacaine and 6 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 7 mL* Withdraw 7 mL to deliver 6.7 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL; PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 60 mg bupivacaine and 1.8 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-304-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 60 mg bupivacaine and 1.8 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike One sterile 3 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 2.3 mL* Withdraw 2.3 mL to deliver 2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL; PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL - NDC 47426-501 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 400 mg bupivacaine and 12 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-501-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 400 mg bupivacaine and 12 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 20 mL sterile vial access needle Two sterile 12 mL Luer Lock syringes Two sterile Luer lock applicators Two sterile syringe tip caps Instructions for Use and Prescribing Information Vial Contents: 14 mL* Withdraw 14 mL to deliver 13.5 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL - NDC 47426-501; PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL - NDC 47426-502 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 300 mg bupivacaine and 9 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-502-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 300 mg bupivacaine and 9 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 20 mL sterile vial access needle One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 10.5 mL* Withdraw 10.5 mL to deliver 10.2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL - NDC 47426-502; PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL - NDC 47426-503 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 200 mg bupivacaine and 6 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-503-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 200 mg bupivacaine and 6 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 10 mL sterile vial access needle One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 7 mL* Withdraw 7 mL to deliver 6.7 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL - NDC 47426-503; PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL - NDC 47426-504 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 60 mg bupivacaine and 1.8 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-504-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 60 mg bupivacaine and 1.8 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 10 mL sterile vial access needle One sterile 3 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 2.3 mL* Withdraw 2.3 mL to deliver 2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL - NDC 47426-504
- 16 HOW SUPPLIED/STORAGE AND HANDLING ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution is a clear, pale-yellow to yellow viscous liquid available in 4 presentations. Each single-dose glass vial is filled with a solution of 29.25 mg/mL bupivacaine and 0.88 mg/mL meloxicam. Each presentation described below is supplied in the ZYNRELEF kit containing a vial (packaged in an individual carton) along with sterile, individually packaged components for administration. Product Presentation (Kit Supplied with Vial Access Needle) Vial Access Needle Provided Luer Lock Syringe(s) Provided Luer Lock Applicator(s) Provided Syringe Tip Cap(s) Provided NDC Bupivacaine/Meloxicam Net Quantity Volume Each ZYNRELEF vial contains overfill to compensate for residual amounts that remain in the vial, vial access needle, Luer lock applicator, and syringe(s) during drug withdrawal and administration 47426-501-02 400 mg/12 mg 14 mL 1 × 20 mL 2 × 12 mL 2 2 47426-502-02 300 mg/9 mg 10.5 mL 1 × 20 mL 1 × 12 mL 1 1 47426-503-01 200 mg/6 mg 7 mL 1 × 10 mL 1 × 12 mL 1 1 47426-504-01 60 mg/1.8 mg 2.3 mL 1 × 10 mL 1 × 3 mL 1 1 Product Presentation (Kit Supplied with Vented Vial Spike) Vented Vial Spike Provided Luer Lock Syringe(s) Provided Luer Lock Applicator(s) Provided Syringe Tip Cap(s) Provided NDC Bupivacaine/Meloxicam Net Quantity Volume Each ZYNRELEF vial contains overfill to compensate for residual amounts that remain in the vial, vented vial spike, Luer lock applicator, and syringe(s) during drug withdrawal and administration 47426-301-02 400 mg/12 mg 14 mL 1 2 × 12 mL 2 2 47426-302-02 300 mg/9 mg 10.5 mL 1 1 × 12 mL 1 1 47426-303-01 200 mg/6 mg 7 mL 1 1 × 12 mL 1 1 47426-304-01 60 mg/1.8 mg 2.3 mL 1 1 × 3 mL 1 1 The following replacement components are individually supplied separate from the kit: Carton containing 5 vented vial spikes Carton containing 10 Luer lock applicators Carton containing 10 sterile 3 mL Luer lock syringes Carton containing 8 sterile 12 mL Luer lock syringes Carton containing 8 sterile 10 mL vial access needles Carton containing 6 sterile 20 mL vial access needles Storage Store ZYNRELEF kits at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. If ZYNRELEF vials are removed from the kit, store them at controlled room temperature. Protect from light during storage.
- PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 400 mg bupivacaine and 12 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-301-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 400 mg bupivacaine and 12 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike Two sterile 12 mL Luer Lock syringes Two sterile Luer lock applicators Two sterile syringe tip caps Instructions for Use and Prescribing Information Vial Contents: 14 mL* Withdraw 14 mL to deliver 13.5 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL
- PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 300 mg bupivacaine and 9 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-302-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 300 mg bupivacaine and 9 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 10.5 mL* Withdraw 10.5 mL to deliver 10.2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL
- PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 200 mg bupivacaine and 6 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-303-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 200 mg bupivacaine and 6 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 7 mL* Withdraw 7 mL to deliver 6.7 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL
- PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 60 mg bupivacaine and 1.8 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-304-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 60 mg bupivacaine and 1.8 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One sterile vented vial spike One sterile 3 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 2.3 mL* Withdraw 2.3 mL to deliver 2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL
- PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL - NDC 47426-501 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 400 mg bupivacaine and 12 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-501-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 400 mg bupivacaine and 12 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 20 mL sterile vial access needle Two sterile 12 mL Luer Lock syringes Two sterile Luer lock applicators Two sterile syringe tip caps Instructions for Use and Prescribing Information Vial Contents: 14 mL* Withdraw 14 mL to deliver 13.5 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 14 mL - NDC 47426-501
- PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL - NDC 47426-502 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 300 mg bupivacaine and 9 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-502-02 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 300 mg bupivacaine and 9 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 20 mL sterile vial access needle One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 10.5 mL* Withdraw 10.5 mL to deliver 10.2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 10.5 mL - NDC 47426-502
- PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL - NDC 47426-503 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 200 mg bupivacaine and 6 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-503-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 200 mg bupivacaine and 6 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 10 mL sterile vial access needle One sterile 12 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 7 mL* Withdraw 7 mL to deliver 6.7 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 7 mL - NDC 47426-503
- PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL - NDC 47426-504 ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution 60 mg bupivacaine and 1.8 mg meloxicam Each mL contains 29.25 mg bupivacaine and 0.88 mg meloxicam Single-Dose Application For Instillation Use Refer to Instructions for Use See Prescribing Information for Dosage, Preparation, and Administration Do Not Substitute Components Use only the supplied components in this kit for preparation Do NOT remove crimp seal NDC 47426-504-01 Store ZYNRELEF kit at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature] Protect from light and moisture Each Kit Contains: One single-dose vial containing 60 mg bupivacaine and 1.8 mg meloxicam in a non-sterile carton. The contents of the vial are sterile. Discard unused portion. Vial Contents Sterile Vial exterior NOT STERILE One 10 mL sterile vial access needle One sterile 3 mL Luer Lock syringe One sterile Luer lock applicator One sterile syringe tip cap Instructions for Use and Prescribing Information Vial Contents: 2.3 mL* Withdraw 2.3 mL to deliver 2 mL Rx Only PRINCIPAL DISPLAY PANEL - Kit Carton - 2.3 mL - NDC 47426-504
Overview
ZYNRELEF (bupivacaine and meloxicam) extended-release solution, for soft tissue or periarticular instillation use, contains bupivacaine, an amide local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). Bupivacaine Bupivacaine is a white to off-white crystalline powder, crystals, or granules. The chemical name for bupivacaine is (±)-1-butyl- N -(2,6-dimethylphenyl)piperidine-2-carboxamide, and its empirical formula is C 18 H 28 N 2 O. The molecular weight of bupivacaine is 288.4. Bupivacaine is sparingly soluble in water and freely soluble in alcohol. Bupivacaine has a log P ow of 1.82 and a pKa of 8.1. Bupivacaine has the following structural formula: Chemical Structure Meloxicam Meloxicam is a pale yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P) app = 0.1 in n -octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2. Meloxicam is chemically designated as 4-hydroxy-2-methyl- N -(5-methyl-2-thiazolyl)-2 H -1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: ZYNRELEF is a sterile, clear, pale yellow to yellow, viscous liquid provided in single-dose vials (10 mL or 20 mL) for instillation into the surgical site. Each mL of the solution contains active ingredients bupivacaine 29.25 mg and meloxicam 0.88 mg; and inactive ingredients tri(ethylene glycol) poly(orthoester) (730 mg), triacetin (293 mg), dimethyl sulfoxide (117 mg), and maleic acid (0.59 mg). Chemical Structure
Indications & Usage
ZYNRELEF is indicated in adults for postsurgical analgesia for up to 72 hours after: soft tissue surgical procedures orthopedic surgical procedures – foot and ankle procedures – other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided [see Warnings and Precautions (5.10) ] ZYNRELEF is indicated in adults for postsurgical analgesia for up to 72 hours after: soft tissue surgical procedures orthopedic surgical procedures – foot and ankle procedures – other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided [see Warnings and Precautions (5.10) ] Limitations of Use Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures ( 1 ). Limitations of Use Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures.
Dosage & Administration
ZYNRELEF is intended for single-dose administration only ( 2.1 ). Administer ZYNRELEF via instillation only. The toxic effects of local anesthetics are additive. Avoid additional use of local anesthetics within 96 hours following administration of ZYNRELEF ( 2.1 ). ZYNRELEF should only be prepared and administered with the components provided in the ZYNRELEF kit ( 2.1 ). ZYNRELEF is applied without a needle into the surgical site following final irrigation and suction and prior to suturing ( 2.1 ). – The recommended dose of ZYNRELEF is up to a maximum dose of 400 mg/12 mg (14 mL) ( 2.4 ). See Full Prescribing Information for important preparation and administration instructions, dose selection, and compatibility considerations ( 2.2 , 2.3 , 2.4 , 2.5 ). 2.1 Important Dosage and Administration Information ADMINISTER ZYNRELEF VIA INSTILLATION ONLY. ZYNRELEF should not be administered via the following routes. – Epidural – Intrathecal – Intravascular – Intra-articular [see Warnings and Precautions (5.10) , Nonclinical Toxicology (13.2) ] – Regional nerve blocks – Pre-incisional or pre-procedural locoregional anesthetic techniques. ZYNRELEF is intended for single-dose administration only. As there is a potential risk of severe, life-threatening adverse reactions associated with the administration of bupivacaine, ZYNRELEF should be administered in a setting where trained personnel and equipment are available to promptly treat patients who show evidence of neurologic or cardiac toxicity [see Overdosage (10) ] . The toxic effects of local anesthetics are additive. Avoid additional use of local anesthetics within 96 hours following administration of ZYNRELEF. Avoid intravascular administration of ZYNRELEF. Convulsions and cardiac arrest have occurred following accidental intravascular injection of bupivacaine and other amide-containing products. Limit exposure to articular cartilage due to the potential risk of chondrolysis [see Warnings and Precautions (5.11) ] . ZYNRELEF is a viscous solution supplied as a kit consisting of a single-dose glass vial, and the following sterile components: Luer lock syringe(s), a vented vial spike or vial access needle, Luer lock cone-shaped applicator(s), and syringe tip cap(s). ZYNRELEF should only be prepared and administered with the components provided in the ZYNRELEF kit. See the ZYNRELEF Instructions for Use included in the kit for complete administration instructions with illustrations. The contents of the ZYNRELEF vial are sterile. The vial exterior is not sterile. Follow your facility's standard operating procedures regarding aseptic drug preparation. Each ZYNRELEF vial contains overfill to compensate for residual amounts that remain in the vial, vented vial spike or vial access needle, Luer lock applicator, and syringe(s) during drug withdrawal and administration. ZYNRELEF is applied without a needle into the surgical site after placement of implant(s) (if applicable), following final irrigation and suctioning, and prior to suturing of each layer, when multiple tissue layers are involved. When ZYNRELEF comes in contact with moisture in the tissues, it becomes more viscous, allowing it to stay in place. ZYNRELEF does not degrade sutures. When tying knots with monofilament sutures, contact with ZYNRELEF may cause knots to loosen or untie due to the viscosity of ZYNRELEF. In vitro studies showed an increase in elasticity with monofilament sutures exposed to ZYNRELEF with unknown clinical significance. Minimize administration of ZYNRELEF near the incision line and wipe off excess ZYNRELEF from the skin prior to suturing. Three (3) or more knots ending in a multi-throw knot (e.g., a Surgeon's knot) are recommended with monofilament sutures. Braided or barbed sutures are recommended, especially for closure of deeper layers. Image 2.2 Preparation Instructions See the ZYNRELEF Instructions for Use included in the kit for complete administration instructions with illustrations. ZYNRELEF is a clear, pale yellow to yellow, viscous liquid. Visually inspect the ZYNRELEF vial for particulate matter and discoloration. Obtain a new vial if particulate matter or discoloration is observed. Prepare vial for filling of syringe(s) by attaching vented vial spike or vial access needle. Syringe attachment for product withdrawal: For vented vial spike, fill syringe with air prior to attaching syringe. Attach syringe to vented vial spike, invert vial and syringe to allow product to fill the vial neck, then push air into vented vial spike prior to withdrawing ZYNRELEF from vial. For vial access needle, do not fill syringe with air prior to attaching syringe. Attach syringe to vial access needle, then invert vial and syringe to allow product to fill the vial neck prior to withdrawing ZYNRELEF from vial. Withdraw dose of ZYNRELEF into syringe. (The dose volume takes into account the potential residual volume in the components.). Withdrawal time using the vial access needle is faster than the vented vial spike. Nominal Dose of Bupivacaine / Meloxicam Number of Syringes and LLAs LLA: Luer lock cone-shaped applicator Per Dose Volume to be Withdrawn 60 mg/ 1.8 mg 1 2.3 mL (using 3 mL syringe provided) 200 mg / 6 mg 1 7 mL (using 12 mL syringe provided) 300 mg/ 9 mg 1 10.5 mL (using 12 mL syringe provided) 400 mg/ 12 mg 2 14 mL (using two 12 mL syringes provided, 7 mL ZYNRELEF per syringe) Repeat steps 1-3 for more than one syringe. Prepare product immediately prior to use and apply syringe tip cap if needed until product delivery. 2.3 Administration Instructions Before administration, remove the syringe tip cap and attach the Luer lock cone-shaped applicator to the syringe. Using the Luer lock cone-shaped applicator attached to the syringe, apply ZYNRELEF to the tissues within the surgical site as follows: For soft tissue procedures, apply ZYNRELEF into the wound prior to closure of each layer within the surgical space. – For abdominal procedures, apply after closure of the peritoneum (if applicable) and avoid administration below the peritoneum. In general for orthopedic procedures, apply ZYNRELEF into the wound and on the periosteum from the proximal to the distal ends of the wound (i.e., beyond the boney repair). – For total joint arthroplasty, apply ZYNRELEF directly into the joint capsule, onto the periosteum, and the antero-, medial-, and lateral tissues (if applicable), after placement of the component(s). – For spinal procedures, apply ZYNRELEF after closure of the paraspinal musculature and again after closure of the subcutaneous fascia. ZYNRELEF must not be applied to the dura or spinal cord. Only apply ZYNRELEF to the tissue layers below the skin incision and not directly onto the subdermal layer or the skin. Minimize administration of ZYNRELEF near the incision line. Use only the amount necessary to coat the tissues, such that ZYNRELEF does not leak from the surgical wound after closure. Wipe off excess ZYNRELEF from the skin prior to or during closure of the wound. 2.4 Dosing Instructions As a general guidance in selecting the proper dosing of ZYNRELEF, the following examples of dosing are provided: For soft tissue surgical procedures, such as: – open inguinal herniorrhaphy: up to 10.5 mL to deliver 300 mg of bupivacaine and 9 mg of meloxicam [see Clinical Studies (14) ] ; – abdominoplasty: up to 14 mL to deliver 400 mg of bupivacaine and 12 mg of meloxicam [see Clinical Studies (14) ] ; – Cesarean section: up to 14 mL to deliver 400 mg of bupivacaine and 12 mg of meloxicam [see Clinical Studies (14) ] ; – augmentation mammoplasty: up to 7 mL per side to deliver total of 400 mg of bupivacaine and 12 mg of meloxicam [see Clinical Studies (14) ] . For orthopedic surgical procedures, such as: – bunionectomy: up to 2.3 mL to deliver 60 mg of bupivacaine and 1.8 mg of meloxicam [see Clinical Studies (14) ] ; – total knee arthroplasty: up to 14 mL to deliver 400 mg of bupivacaine and 12 mg of meloxicam [see Clinical Studies (14) ] ; – total shoulder arthroplasty: up to 14 mL to deliver 400 mg of bupivacaine and 12 mg of meloxicam [see Clinical Studies (14) ] ; – 1- to 3-level spinal surgery: up to 7 mL to deliver 200 mg bupivacaine and 6 mg meloxicam [see Clinical Studies (14) ] . 2.5 Compatibility Considerations Do not dilute ZYNRELEF. ZYNRELEF is a nonaqueous solution. It cannot be mixed with water, saline, or other local anesthetics as the product will become more viscous and difficult to administer. When a topical antiseptic such as povidone iodine (e.g., Betadine ® ) is applied, the site should be allowed to dry before a local anesthetic, including ZYNRELEF, is administered into the site. When administered in recommended doses and concentrations, ZYNRELEF does not ordinarily produce irritation or tissue damage. ZYNRELEF is compatible with: All components of the ZYNRELEF kit, including syringes, Luer lock cone-shaped applicator, vented vial spike, vial access needle, and syringe tip caps. Surgical mesh materials, including polypropylene (Prolene ® ), Gore-tex, and polyester. Silicone membranes. Bone cement. Metal alloys used in surgical implants.
Warnings & Precautions
Dose-Related Toxicity : Monitor cardiovascular and respiratory vital signs and patient's state of consciousness after application of ZYNRELEF ( 5.3 ). When using ZYNRELEF with other local anesthetics, overall local anesthetic exposure must be considered through 72 hours ( 5.3 ). Hepatotoxicity : If abnormal liver tests persist or worsen, perform a clinical evaluation of the patient ( 5.5 ). Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure ( 5.6 , 7 ). Heart Failure and Edema : Avoid use of ZYNRELEF in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure ( 5.7 ). Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ZYNRELEF in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function ( 5.8 ). Anaphylactic Reactions : Seek emergency help if an anaphylactic reaction occurs ( 5.9 ). Risk of Joint Cartilage Necrosis and Degeneration with Unapproved Intra-articular Use : Animal studies evaluating the effects of ZYNRELEF following intra-articular administration in the knee joint demonstrated cartilage necrosis and degeneration ( 5.10 , 13.2 ). Chondrolysis : Limit exposure to articular cartilage due to the potential risk of chondrolysis ( 5.11 ). Methemoglobinemia : Cases of methemoglobinemia have been reported in association with local anesthetic use ( 5.12 ). Serious Skin Reactions : NSAIDs, including meloxicam, can cause serious skin adverse reactions. If symptoms present, evaluate clinically ( 5.14 ). Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) : If symptoms are present, evaluate clinically ( 5.15 ). Fetal Toxicity : Limit use of NSAIDs, including ZYNRELEF, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the ductus arteriosus ( 5.16 , 8.1 ). Hematologic Toxicity : Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia ( 5.17 ). 5.1 Cardiovascular (CV) Thrombotic Events with NSAID Use Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. The risk of these events following single-dose local application of ZYNRELEF is uncertain. To minimize the potential risk for an adverse CV event in NSAID-treated patients, do not exceed the recommended dose. Physicians and patients should remain alert for the development of such events following treatment with ZYNRELEF, even in the absence of previous CV symptoms. Inform patients about the signs and symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as meloxicam, increases the risk of serious gastrointestinal (GI) events [see Warnings and Precautions (5.2) ] . Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. ZYNRELEF is contraindicated in the setting of CABG [see Contraindications (4) ] . Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up. Avoid the use of ZYNRELEF in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ZYNRELEF is used in patients with a recent MI, monitor patients for signs of cardiac ischemia. The risk of these events following single-dose local application of ZYNRELEF is uncertain. 5.2 Gastrointestinal Bleeding, Ulceration, and Perforation with NSAID Use NSAIDs, including meloxicam in ZYNRELEF, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2 to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk. Risk Factors for GI Bleeding, Ulceration, and Perforation Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most post marketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding. Strategies to Minimize the GI Risks in NSAID-treated Patients Use the recommended dose for each indicated surgical procedure. Avoid administration of analgesic doses of more than one NSAID at a time. If additional NSAID medication is indicated in the postoperative period, monitor patients for signs and symptoms of NSAID-related GI adverse reactions. Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs. Remain alert for signs and symptoms of GI ulceration and bleeding following treatment with ZYNRELEF. If a serious GI adverse event is suspected, promptly initiate evaluation and treatment. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [see Drug Interactions (7) ] . 5.3 Dose-Related Toxicity The safety and effectiveness of local anesthetics depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. The toxic effects of local anesthetics are additive. Avoid additional local anesthetic administration within 96 hours following ZYNRELEF instillation. If additional local anesthetic administration with ZYNRELEF cannot be avoided based on clinical need, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after administration of ZYNRELEF. Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest, and, possibly, death. 5.4 Risk of Use in Patients with Impaired Cardiovascular Function Patients with impaired cardiovascular function (e.g., hypotension, heart block) may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by ZYNRELEF. Monitor patients closely for blood pressure, heart rate, and ECG changes. 5.5 Hepatotoxicity Local Anesthetics, Including Bupivacaine Because amide-type local anesthetics such as bupivacaine are metabolized by the liver, these drugs should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. NSAIDs Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including meloxicam. The risk of these events following single-dose local application of ZYNRELEF is uncertain. Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), perform a clinical evaluation of the patient [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ] . 5.6 Hypertension NSAIDs, including meloxicam in ZYNRELEF, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [see Drug Interactions (7) ] . Monitor blood pressure (BP) after administration of ZYNRELEF. 5.7 Heart Failure and Edema The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of meloxicam may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [see Drug Interactions (7) ] . The risk of these events following single-dose local application of ZYNRELEF is uncertain. Avoid the use of ZYNRELEF in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ZYNRELEF is used in patients with severe heart failure, monitor patients for signs of worsening heart failure. 5.8 Renal Toxicity and Hyperkalemia Renal Toxicity ZYNRELEF is a single-use product that contains an NSAID. Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. The renal effects of meloxicam may hasten the progression of renal dysfunction in patients with preexisting renal disease. Because some meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function. Correct volume status in dehydrated or hypovolemic patients prior to initiating ZYNRELEF. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of ZYNRELEF [see Drug Interactions (7) ] . Avoid the use of ZYNRELEF in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If ZYNRELEF is used in patients with advanced renal disease, monitor patients for signs of worsening renal function [see Clinical Pharmacology (12.3) ] . Hyperkalemia Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. 5.9 Anaphylactic Reactions NSAIDs Meloxicam, contained in ZYNRELEF, has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma [see Contraindications (4) ] . Seek emergency help if an anaphylactic reaction occurs. 5.10 Risk of Joint Cartilage Necrosis with Unapproved Intra-articular Use The safety and effectiveness of intra-articular use of ZYNRELEF in orthopedic surgical procedures other than for foot and ankle procedures have not been established, and ZYNRELEF is not approved for use via other intra-articular administration routes. Animal studies evaluating the effects of ZYNRELEF following intra-articular administration in the knee joint demonstrated cartilage necrosis and degeneration [see Nonclinical Toxicology (13.2) ] . 5.11 Chondrolysis Limit exposure to articular cartilage due to the potential risk of chondrolysis. Intra-articular infusions of local anesthetics, following arthroscopic and other surgical procedures is an unapproved use, and there have been post marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of glenohumeral chondrolysis have been described in pediatric patients and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are associated with chondrolysis. The time of onset of symptoms, such as joint pain, stiffness, and loss of motion can be variable, but may begin as early as the 2 nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who have experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. 5.12 Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue any oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. 5.13 Exacerbation of Asthma Related to Aspirin Sensitivity A subpopulation of patients with asthma may have aspirin-sensitive asthma, which may include: chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, NSAIDs are contraindicated in patients with this form of aspirin sensitivity [see Contraindications (4) ] . When ZYNRELEF is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for exacerbation of asthma symptoms. 5.14 Serious Skin Reactions NSAIDs, including meloxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions. ZYNRELEF is contraindicated in patients with previous serious skin reactions to NSAIDs [see Contraindications (4) ] . 5.15 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ZYNRELEF. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, evaluate the patient immediately and treat as clinically indicated. 5.16 Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus Avoid use of NSAIDs, including ZYNRELEF, in pregnant women at about 30 weeks gestation and later. NSAIDs, including ZYNRELEF, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs, including ZYNRELEF, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ZYNRELEF use to the lowest effective dose. Because meloxicam can be detected in plasma beyond 48 hours after administration of ZYNRELEF, consider ultrasound monitoring for oligohydramnios. If oligohydramnios occurs, follow up according to clinical practice [see Use in Specific Populations (8.1) ] . 5.17 Hematologic Toxicity Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with ZYNRELEF has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. NSAIDs, including meloxicam, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7) ] . 5.18 Masking of Inflammation and Fever The pharmacological activity of ZYNRELEF in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.
Boxed Warning
RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ( 5.2 ) Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1) ] . ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1) ] . Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2) ] .
Contraindications
ZYNRELEF is contraindicated in: Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF [see Warnings and Precautions (5.9 , 5.14) ] . Patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.9) ] . Patients undergoing obstetrical paracervical block anesthesia. The use of bupivacaine in this technique has resulted in fetal bradycardia and death [see Use in Specific Populations (8.1) ] . Patients undergoing coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1) ] . ZYNRELEF is contraindicated for: Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF ( 4 ) Patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients ( 4 ) Patients undergoing obstetrical paracervical block anesthesia ( 4 ) Patients undergoing coronary artery bypass graft (CABG) surgery ( 4 )
Adverse Reactions
The following serious adverse reactions have been associated with bupivacaine HCl or meloxicam and are discussed in greater detail in other sections of the labeling: Cardiovascular System Reactions [see Warnings and Precautions (5.1 , 5.4) ] Gastrointestinal Bleeding, Ulceration, and Perforation [see Warnings and Precautions (5.2) ] Dose-Related Toxicity [see Warnings and Precautions (5.3) ] Hepatotoxicity [see Warnings and Precautions (5.5) ] Hypertension [see Warnings and Precautions (5.6) ] Heart Failure and Edema [see Warnings and Precautions (5.7) ] Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.8) ] Anaphylactic Reactions [see Warnings and Precautions (5.9) ] Chondrolysis [see Warnings and Precautions (5.11) ] Methemoglobinemia [see Warnings and Precautions (5.12) ] Exacerbation of Asthma Related to Aspirin Sensitivity [see Warnings and Precautions (5.13) ] Serious Skin Reactions [see Warnings and Precautions (5.14) ] Drug Reaction with Eosinophilia and Systemic Toxicity (DRESS) [see Warnings and Precautions (5.15) ] Fetal Toxicity [see Warnings and Precautions (5.16) ] Hematologic Toxicity [see Warnings and Precautions (5.17) ] Most common adverse reactions (incidence ≥5%) are: Soft tissue procedures: vomiting ( 6.1 ). Orthopedic procedures: constipation and headache ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Heron Therapeutics, Inc. at 1-844-437-6611 and www.ZYNRELEF.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The safety of ZYNRELEF has been evaluated in a total of 1627 patients undergoing various surgical procedures across 14 clinical studies including 7 randomized, double-blind, bupivacaine- and placebo-controlled and saline placebo-controlled studies designed to investigate ZYNRELEF to reduce postoperative pain for 72 hours and the need for opioid analgesics, of whom 1183 received ZYNRELEF by instillation. Patients treated with ZYNRELEF ranged in age from 18 to 85 years (median age 51 years), with 53.0% female, 82.1% White, 13.7% African-American, and 4.3% all other races. Common Adverse Reactions The safety of ZYNRELEF has been evaluated in 1064 patients who received ZYNRELEF in single doses up to 400 mg/12 mg via instillation into the surgical site, including 533 patients undergoing a soft tissue surgical procedure (herniorrhaphy, abdominoplasty, augmentation mammoplasty, or Cesarean section) and 531 patients undergoing an orthopedic surgical procedure (bunionectomy, total knee arthroplasty, total shoulder arthroplasty, or lumbar spinal surgery). The most common adverse reactions (incidence greater than or equal to 5% and higher than placebo) following ZYNRELEF administration among patients undergoing soft tissue procedures was vomiting and among patients undergoing orthopedic procedures were constipation and headache. The safety of ZYNRELEF as part of a scheduled, non-opioid multimodal analgesic regimen including 1 or more other NSAIDs has been evaluated in a total of 473 patients undergoing soft tissue procedures or orthopedic procedures. NSAIDs included ibuprofen, ketorolac, and celecoxib. In these studies, the most common adverse reactions (incidence of greater than or equal to 2%) potentially associated with NSAIDs were pruritus and postoperative anemia. Rare but clinically serious NSAID-related adverse events, including peptic ulcer hemorrhage, gastritis requiring hospitalization, hematemesis and melena, gastrointestinal hemorrhage, and increased hepatic enzymes, were observed in subjects with predisposing risk factors (i.e., concomitant comorbidities and/or on concomitant medications such as anticoagulant and/or antiplatelet medications) that increased the risk for NSAID-related gastrointestinal toxicity. Adverse Reactions Reported in Phase 3 and 2b Placebo-controlled Trials Three randomized, bupivacaine-controlled and saline placebo-controlled studies were conducted in patients undergoing bunionectomy (STUDY 1, Table 1 and Table 2), open inguinal herniorrhaphy (STUDY 2, Table 3), and total knee arthroplasty (STUDY 3, Table 4). The bunionectomy procedures in STUDY 1 were performed under regional anesthesia, a lidocaine Mayo block, and intravenous sedation. The herniorrhaphy procedures in STUDY 2 were performed under general anesthesia. The total knee arthroplasty procedures in STUDY 3 were performed under either general or spinal anesthesia. Patients in STUDY 1 and STUDY 2 were allowed opioid rescue with intravenous (IV) morphine and oral oxycodone, and/or non-opioid rescue with oral acetaminophen. Patients in STUDY 3 were pretreated with oral pregabalin and acetaminophen, and allowed opioid rescue with IV morphine and oral oxycodone postoperatively. Table 1. Adverse Reactions with ZYNRELEF in Study 1 (Bunionectomy) Occurring with ≥5% Incidence and Higher than with Saline Placebo Preferred Term Saline Placebo (N=101), % Bupivacaine HCl 50 mg (N=154), % ZYNRELEF 60 mg/1.8 mg (N=157), % Dizziness 18 23 22 Incision site edema 13 14 17 Headache 10 13 14 Incision site erythema 8 12 13 Bradycardia 6 8 8 Impaired healing 1 4 6 Muscle twitching 5 5 6 In STUDY 1, bone healing was assessed by X-ray on Days 28 and 42. There was no clinically meaningful difference in bone healing between treatment groups. A total of 4 subjects had delayed bone healing: 1 in the ZYNRELEF group, 1 in the saline placebo group, and 2 in the bupivacaine HCl group. The incidence of local inflammatory adverse events was higher in the ZYNRELEF group than in either control group (Table 2). Table 2. Incidence of Local Inflammatory Adverse Events with ZYNRELEF in Study 1 (Bunionectomy) Occurring with ≥2% Incidence and Higher than with Saline Placebo Saline Placebo (N=101), % Bupivacaine HCl 50 mg (N=154), % ZYNRELEF 60 mg/1.8 mg (N=157), % Incision site edema 13 14 17 Incision site erythema 8 12 13 Impaired healing 1 4 6 Incision site cellulitis 1 1 4 Wound dehiscence 2 1 4 Incision site infection 0 1 3 Table 3. Adverse Reactions with ZYNRELEF in Study 2 (Herniorrhaphy) Occurring with ≥5% Incidence and Higher than with Saline Placebo Preferred Term Saline Placebo (N=82), % Bupivacaine HCl 75 mg (N=173), % ZYNRELEF 300 mg/9 mg (N=163), % Headache 12 14 13 Bradycardia 7 9 9 Dysgeusia 4 12 9 Skin odor abnormal All TEAEs of skin odor abnormal were recorded at a single site. 1 1 8 Table 4. Adverse Reactions with ZYNRELEF in Study 3 (Total Knee Arthroplasty) Occurring with ≥5% Incidence and Higher than with Saline Placebo Preferred Term Saline Placebo (N=53), % Bupivacaine HCl 125 mg (N=55), % ZYNRELEF 400 mg/12 mg (N=58), % Nausea 47 55 50 Constipation 23 33 24 Vomiting 19 27 26 Hypertension 15 13 19 Pyrexia 4 15 14 Leukocytosis 0 2 7 Pruritis 2 5 7 Headache 0 7 7 Anemia 2 0 5 Hyperhidrosis 4 0 5 Hypotension 4 2 5 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ZYNRELEF or other products containing NSAIDs. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. ZYNRELEF Injury, Poisoning, and Procedural Complications: Wound necrosis, Wound dehiscence. Surgical and Medical Procedures: Post-procedural drainage. NSAIDs Skin and Appendages: Exfoliative dermatitis, SJS, TEN, and FDE [see Warnings and Precautions (5.14) ] .
Drug Interactions
Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs) : Monitor patients for bleeding who are concomitantly taking ZYNRELEF with drugs that interfere with hemostasis ( 7.2 ). ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), or Beta-Blockers : Concomitant use with ZYNRELEF may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7.2 ). ACE Inhibitors and ARBs : Concomitant use with ZYNRELEF in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function ( 7.2 ). Diuretics : NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effect ( 7.2 ). 7.1 Bupivacaine Drug Interactions In clinical studies, other local anesthetics (including ropivacaine and lidocaine) have been administered before, during, or after application of ZYNRELEF without evidence of local anesthetic systemic toxicity. Administration of ZYNRELEF with other formulations of local anesthetics, including bupivacaine liposome injectable suspension, has not been studied [see Warnings and Precautions (5.3) ] . The toxic effects of local anesthetics are additive. Avoid additional use of local anesthetics within 96 hours following administration of ZYNRELEF. If co-administration cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) and Overdosage (10) ] . Patients who are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics (Table 5). Table 5. Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.2 Meloxicam Drug Interactions See Table 6 for clinically significant drug interactions with meloxicam. Table 6. Clinically Significant Drug Interactions with Meloxicam Drugs that Interfere with Hemostasis Clinical Impact: Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of ZYNRELEF with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.17)] . Aspirin Clinical Impact: In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2) ] . Intervention: If aspirin is indicated in the postoperative period, monitor patients for signs and symptoms of GI bleeding [see Clinical Pharmacology (12.3) ] . ACE Inhibitors, Angiotensin Receptor Blockers, or Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, coadministration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Intervention: During concomitant use of ZYNRELEF and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. During concomitant use of ZYNRELEF and ACE inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6) ] . When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. Diuretics Clinical Impact: Clinical studies, as well as post-marketing observations, showed that NSAIDs have reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. Intervention: During concomitant use of ZYNRELEF with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects. Digoxin Clinical Impact: The concomitant use of NSAIDS with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Intervention: During concomitant use of ZYNRELEF and digoxin, monitor serum digoxin levels. Lithium Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis [see Clinical Pharmacology (12.3) ] . Intervention: Monitor patients on lithium for signs of lithium toxicity. Methotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). Intervention: During concomitant use of ZYNRELEF and methotrexate, monitor patients for methotrexate toxicity. Cyclosporine Clinical Impact: Concomitant use of NSAIDs and cyclosporine may increase cyclosporine's nephrotoxicity. Intervention: During concomitant use of ZYNRELEF and cyclosporine, monitor patients for signs of worsening renal function. NSAIDs and Salicylates Clinical Impact: Concomitant use of meloxicam with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity [see Warnings and Precautions (5.2) ] . Intervention: If additional NSAID or salicylate medication is indicated in the postoperative period, monitor patients for signs and symptoms of GI toxicity [see Clinical Pharmacology (12.3) ] . Pemetrexed Clinical Impact: Concomitant use of NSAIDs and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). Intervention: During concomitant use of ZYNRELEF and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. Patients taking meloxicam should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration. In patients with creatinine clearance below 45 mL/min, the concomitant administration of meloxicam with pemetrexed is not recommended.
Storage & Handling
Storage Store ZYNRELEF kits at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. If ZYNRELEF vials are removed from the kit, store them at controlled room temperature. Protect from light during storage.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.